Guest
In this episode, I discuss what psilocybin is (chemically) and how it works at the cellular and neural circuit level to trigger neuroplasticity, which is our brain’s ability to rewire itself in ways that lead to long-lasting shifts in our emotional, cognitive and behavioral patterns and abilities. I discuss the emerging clinical trial evidence for the use of psilocybin in the treatment of depression, addictions and other psychiatric challenges. I explain the typical duration and phases of a psilocybin journey, the different categories of dosages often used and I explain the importance of set, setting and support when using psychedelics. I explain which groups of people place themselves at great risk by taking psilocybin as well as groups that could benefit, and I highlight the rapidly changing legal and medical landscape around psilocybin. This episode is a thorough exploration of psilocybin from the scientific and clinical literature perspective and ought to be of interest to anyone curious about psilocybin, mental health, neuroplasticity and/or psychedelics more generally. #HubermanLab #Science Thank you to our sponsors AG1 (Athletic Greens): Eight Sleep: ROKA: HVMN: code: “Huberman” LMNT: Supplements from Momentous Social & Website Instagram: Twitter: Facebook: LinkedIn: Website: Newsletter: Articles The neural basis of psychedelic action: The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers: Increased low-frequency brain responses to music after psilocybin therapy for depression: Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression: Brief structured respiration practices enhance mood and reduce physiological arousal: Therapeutic use of psilocybin: Practical considerations for dosing and administration: Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo: Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics: Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression: Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: The costs and benefits of psychedelics on cognition and mood: Other Resources The Physiological Sigh: Dr. Matthew Johnson: Psychedelic Medicine: Timestamps 00:00:00 Psilocybin, Legal Considerations 00:08:32 Sponsors: Eight Sleep, ROKA, HVMN 00:12:00 Psilocybin Becomes Psilocin in the Gut, Serotonin 00:17:00 The Serotonin 2A Receptor, Therapeutic Outcomes SSRIs vs. Psilocybin 00:21:40 Serotonin Receptor Expression; Visual Hallucinations & Eyes Closed 00:27:21 Safety & Cautions for Specific Patient Populations 00:29:13 Sponsor: AG1 (Athletic Greens) 00:30:28 Psilocybin, “Magic Mushrooms” Dosing, Micro-Dosing, “Heroic Doses” 00:36:21 Psychedelic Journey: Set, Setting & Support 00:43:43 Music & the Psilocybin Journey; Duration of Effects 00:48:58 Psilocybin & the Brain: Subjective Experiences, Perception 00:58:36 Sponsor: LMNT 00:59:48 Brain Networks & Therapeutic Outcomes 01:05:23 Creativity; Music, Emotionality & Psychedelic Journeys 01:12:39 Depression & Psychedelics as Neuroplasticity “Wedge” 01:16:53 Positive Psychedelic Journeys, Unity, “Oceanic Boundlessness” 01:25:23 “Bad Trips”, Anxiety & Physiological Sighs 01:32:57 Therapeutic Use of Psilocybin 01:36:11 Neuroplasticity, Structural Brain Changes & Psilocybin 01:48:08 Psychedelics: Therapeutic Breakthroughs & Depression 01:56:37 Combining Psilocybin Therapy & Talk Therapy, Antidepressant Effects 02:03:11 Psilocybin Experience & Mental Health 02:06:42 Zero-Cost Support, YouTube Feedback, Spotify & Apple Reviews, Sponsors, Momentous, Neural Network Newsletter, Social Media Title Card Photo Credit: Mike Blabac - Disclaimer:
